Nanotechnology Now - Press Release: AMAG Pharmaceuticals, Inc. to Present at the Jefferies 2nd Annual Healthcare Conference

Home > Press > AMAG Pharmaceuticals, Inc. to Present at the Jefferies 2nd Annual Healthcare Conference

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira MD, President and Chief Executive Officer, will present an overview of the Company at the Jefferies 2nd Annual Healthcare Conference on Thursday, June 25 at 11:45 a.m. ET. The conference is being held June 24-26, 2008 in New York City.

AMAG Pharmaceuticals, Inc. to Present at the Jefferies 2nd Annual Healthcare Conference

Cambridge, MA | Posted on June 18th, 2008

A live audio webcast of the presentation will be accessible through the Investors section of the Company's website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until July 4, 2008.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic agent in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA) in December 2007, which was accepted for filing by the FDA in February 2008.

For more information, please click here

Contacts:
for AMAG Pharmaceuticals
Carol Miceli
617-498-3361

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: